Application of a biodegradable macromolecular contrast agent in dynamic contrast-enhanced MRI for assessing the efficacy of indocyanine green-enhanced photothermal cancer therapy

✍ Scribed by Yi Feng; Lyska Emerson; Eun-Kee Jeong; Dennis L. Parker; Zheng-Rong Lu

• Publisher: John Wiley and Sons
• Year: 2009
• Tongue: English
• Weight: 162 KB
• Volume: 30
• Category: Article
• ISSN: 1053-1807
• DOI: 10.1002/jmri.21838

✦ Synopsis

Abstract

Purpose

To investigate the effectiveness of a polydisulfide‐based biodegradable macromolecular contrast agent, (Gd‐DTPA)‐cystamine copolymers (GDCC), in assessing the efficacy of indocyanine green‐enhanced photothermal cancer therapy using dynamic contrast‐enhanced magnetic resonance imaging (DCE‐MRI).

Materials and Methods

Breast cancer xenografts in mice were injected with indocyanine green and irradiated with a laser. The efficacy was assessed using DCE‐MRI with GDCC of 40 kDa (GDCC‐40) at 4 hours and 7 days after the treatment. The uptake of GDCC‐40 by the tumors was fit to a two‐compartment model to obtain tumor vascular parameters, including fractional plasma volume (f^PV^), endothelium transfer coefficient (K^PS^), and permeability surface area product (PS).

Results

GDCC‐40 resulted in similar tumor vascular parameters at three doses, with larger standard deviations at lower doses. The values of f^PV^, K^PS^, and PS of the treated tumors were smaller (P < 0.05) than those of untreated tumors at 4 hours after the treatment and recovered to pretreatment values (P > 0.05) at 7 days after the treatment.

Conclusion

DCE‐MRI with GDCC‐40 is effective for assessing tumor early response to dye‐enhanced photothermal therapy and detecting tumor relapse after the treatment. GDCC‐40 has a potential to noninvasively monitor anticancer therapies with DCE‐MRI. J. Magn. Reson. Imaging 2009;30:401–406. © 2009 Wiley‐Liss, Inc.